Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Tirzepatide: A Research Guide to the Dual GLP-1 / GIP Agonist

Short answer: tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide developed by Eli Lilly, the first dual agonist in its class - it simultaneously activates both the GLP-1 and GIP receptors. It is FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (chronic weight management), with the head-to-head SURMOUNT-5 trial showing a greater mean weight reduction over 72 weeks than once-weekly semaglutide. New-U catalogues research-grade tirzepatide as Tirzepatide - lyophilised reference peptide, sealed vials, per-batch CoA, research use only.

Tirzepatide is the single most-searched peptide on the internet in 2026, with roughly 1 million monthly Google queries in the United States alone - nearly double the next compound in the category. That demand sits across two distinct populations: clinicians prescribing the approved branded product (Mounjaro, Zepbound), and the research community studying the underlying 39-amino-acid molecule. This guide is for the latter. It explains the mechanism, summarises the pivotal Phase 3 evidence (SURPASS, SURMOUNT, SURMOUNT-5), and frames what tirzepatide looks like as a research reference compound - catalogued on our site as Tirzepatide. For the broader GLP-1 class explainer see Is Ozempic a Peptide?; for the side-by-side single-vs-dual mechanism comparison see Semaglutide vs Tirzepatide.

Plain-English summary. Tirzepatide is an approved medicine in the United States, the United Kingdom and many other jurisdictions when supplied through licensed channels as Mounjaro or Zepbound. Research-grade tirzepatide, sold as a lyophilised reference peptide for laboratory use, is a separate non-medicine category. New-U sells only the research reagent - not the medicine - with no human-use claims, no dosing guidance and no therapeutic protocol. This page is general information, not legal or medical advice.

What tirzepatide actually is

Tirzepatide, developmental code LY3298176 , is a 39-amino-acid synthetic peptide modelled on the native GIP backbone. A C20 fatty acid is attached via a γ-Glu-2xOEG linker at Lys20; that lipid tail drives reversible albumin binding , which extends the half-life to roughly 5 days . The long half-life is what enables once-weekly subcutaneous administration in the licensed product. Structurally, tirzepatide is not a GLP-1 analogue with a GIP feature bolted on - it is a GIP-derived sequence engineered to acquire potent GLP-1 receptor binding while retaining native GIP activity.

That dual-agonist property is the entire point. GLP-1 and GIP are the two principal incretins - gut-derived hormones released after a meal that potentiate glucose-dependent insulin secretion. Native GIP loses activity in type-2 diabetes; restoring GIP-receptor signalling alongside GLP-1 activation is hypothesised to be the mechanistic reason tirzepatide produces larger metabolic effects than GLP-1 mono-agonists. The full mechanism is reviewed in the StatPearls tirzepatide chapter.

Mechanism of action, in plain English

Tirzepatide does four things simultaneously:

Slows gastric emptying. Food sits longer in the stomach; satiety hormones get more time to register.

Central signalling. GLP-1 receptors in the hypothalamus and brainstem are investigated in relation to energy-intake endpoints measured in published studies.

Potentiates glucose-dependent insulin secretion. β-cell response to a glucose load is amplified, without the off-target hypoglycaemia risk of insulin or sulfonylureas.

Suppresses glucagon in a glucose-dependent manner, reducing hepatic glucose output.

The dual GIP arm adds an additional set of effects on adipose tissue glucose handling and energy expenditure. The net result, as documented in the Phase 3 programme, is a larger mean body-weight reduction than any approved GLP-1 mono-agonist had previously demonstrated.

The Phase 3 evidence: SURPASS and SURMOUNT

Tirzepatide’s approval rests on two trial programmes:

SURPASS (type-2 diabetes, n > 13,000 across SURPASS-1 through SURPASS-6). At the 15 mg weekly dose, tirzepatide produced HbA1c reductions of ~2.1–2.4% from baseline, larger than insulin glargine and larger than semaglutide 1.0 mg in the SURPASS-2 head-to-head.

SURMOUNT (chronic weight management). SURMOUNT-1 reported mean weight reduction of ~20.9% at the 15 mg dose over 72 weeks in adults with obesity without diabetes, with a placebo-corrected difference of around 17.8 percentage points - the largest effect ever recorded for a single pharmacological agent in an obesity trial at the time of publication.

The head-to-head SURMOUNT-5 trial (NEJM, 2025) compared tirzepatide and semaglutide directly over 72 weeks. Tirzepatide produced a significantly greater mean reduction in body weight than semaglutide, with the magnitude of the difference roughly mirroring what the cross-trial comparisons had already suggested.

Tirzepatide vs semaglutide vs retatrutide

The incretin landscape now spans three receptor profiles and three approval stages:

Compound Receptor profile Amino acids Status Semaglutide Semaglutide GLP-1 only (mono-agonist) 31 Approved (Ozempic, Wegovy, Rybelsus) Tirzepatide Tirzepatide GLP-1 + GIP (dual agonist) 39 Approved (Mounjaro, Zepbound) Retatrutide Retatrutide GLP-1 + GIP + glucagon (triple agonist) 39 Phase 3, no approval

Each step up the agonist count adds an additional metabolic pathway: semaglutide acts on GLP-1 alone; tirzepatide adds GIP-receptor signalling; retatrutide adds glucagon-receptor agonism, which contributes hepatic thermogenesis and an additional energy-expenditure arm. For the regulatory framing of each one in the UK specifically, see Where to Buy Retatrutide in the UK.

Pharmacokinetics: why once-weekly works

Native GLP-1 has a circulating half-life of roughly 2 minutes - it is degraded almost instantly by DPP-4. Tirzepatide gets to ~5 days by a combination of three engineering choices: (1) the C20 fatty acid for albumin binding, (2) Aib substitutions at residues 2 and 13 that block DPP-4 cleavage, and (3) the γ-Glu-2xOEG linker that positions the fatty acid for optimal albumin affinity. Steady-state plasma concentration is reached after roughly 4 weeks of weekly dosing.

Tirzepatide as a research compound

On the New-U catalogue, the research-grade reference peptide is listed as Tirzepatide . Same 39-amino-acid sequence, same dual GLP-1/GIP receptor mechanism, same molecule that Eli Lilly studies as LY3298176, supplied here as a research compound within our incretin reference range. The product is a sealed glass vial of lyophilised peptide for laboratory use only.

>99% HPLC purity , independently verified by Janoshik Analytics and Freedom Diagnostics , with the per-batch Certificate of Analysis published online.

Sealed 10-vial packs , lyophilised, multiple mg/vial tiers.

Tracked worldwide delivery , with flat-rate UK / US / EU options and free shipping over the threshold for each market.

No human-use, dosing, therapeutic or weight-loss claims anywhere on the listing. By design.

Operated by a Wyoming-registered distributor - a verifiable legal entity, not an anonymous storefront.

The reason for the research-compound posture is the same reason it matters everywhere else in this catalogue: a peptide marketed for human use is a medicine, and selling an unapproved medicine is the line both the FDA and MHRA actually enforce. A lyophilised reference peptide labelled research use only, not for human consumption sits in a separate, lawful category. See Are Peptides Legal? for the US framing and Are Peptides Legal in the UK? for the UK.

How to verify tirzepatide purity

For a 39-amino-acid peptide with a fatty acid tail, the purity questions are:

HPLC purity >99% by reversed-phase chromatography. Anything below that band fails the credible-standard test.

Mass-spec identity match to the calculated monoisotopic mass of the C225H348N48O68 sequence (~4,813 Da). A wrong mass means the molecule is not tirzepatide.

Named third-party lab on the CoA. Janoshik Analytics and Freedom Diagnostics are the two most cited in the research-compound supply chain.

CoA published for the batch on sale. A “CoA on file” with no batch link proves nothing.

Our walkthrough of every line item is in How to Read a Certificate of Analysis.

Red flags on tirzepatide listings

The same scam patterns appear across the entire GLP-1 cluster. Walk away from any tirzepatide listing that:

Markets “Mounjaro” or “Zepbound” outside a licensed pharmacy. Those are Eli Lilly trade names for the licensed medicine, not for research peptide.

Quotes dosing protocols, mg-per-week schedules, titration ladders or weight-loss promises . Those re-characterise the product as an unlicensed medicine.

Has no CoA , or shows a generic stock CoA with no batch number tied to your order.

Quotes a price so far below the rest of the market that the implied purity figure could not be third-party certified.

Operates from a Telegram-only channel, a fresh Shopify with no legal entity in the footer, or a domain registered weeks ago.

Sells “pre-mixed” or “ready-to-inject” pens. Lyophilised reference peptide ships dry in a sealed vial; pre-mixed solutions move the listing into medicine territory.

Storage & handling of lyophilised tirzepatide

Lyophilised tirzepatide is robust at standard freezer temperatures but should be handled like the long-chain modified peptide it is. Keep sealed vials at −20°C for long-term storage. Allow vials to reach room temperature before opening so condensation does not enter the vial. Reconstitute only the volume needed; once reconstituted, store at 2–8°C and protect from light. Our full handling reference is in How to Store Peptides.

Frequently Asked Questions

What is tirzepatide? A 39-amino-acid synthetic peptide developed by Eli Lilly (developmental code LY3298176). It is a dual agonist of the GLP-1 and GIP receptors, marketed as Mounjaro for type-2 diabetes and Zepbound for chronic weight management.

How is tirzepatide different from semaglutide? Semaglutide is a single GLP-1 agonist. Tirzepatide adds GIP-receptor agonism - the “dual” in dual incretin agonist. In SURMOUNT-5 (NEJM, 2025) tirzepatide produced a significantly greater mean weight reduction than semaglutide over 72 weeks.

What is tirzepatide’s half-life? Approximately 5 days, enabling once-weekly subcutaneous dosing. The long half-life comes from a C20 fatty acid moiety that drives reversible albumin binding.

Is tirzepatide a research compound on this site? Yes. New-U catalogues research-grade tirzepatide as Tirzepatide, lyophilised reference peptide with the per-batch Certificate of Analysis published online. Sold research use only.

How do I verify tirzepatide purity? Demand a per-batch CoA showing >99% HPLC purity and a mass-spec identity match to the calculated monoisotopic mass, from a named third-party lab. See how to read a CoA.

Primary sources & further reading

New England Journal of Medicine - SURMOUNT-5: Tirzepatide vs Semaglutide for Obesity (Aronne et al., 2025)

NEJM - SURMOUNT-1: Tirzepatide Once Weekly for Obesity (Jastreboff et al., 2022)

NIH/NCBI Bookshelf - StatPearls: Tirzepatide

U.S. National Library of Medicine - PubMed: tirzepatide / LY3298176

ClinicalTrials.gov - tirzepatide trial registry

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way. Mounjaro and Zepbound are trade names of Eli Lilly and Company; New-U sells research-grade reference peptide only, not the licensed medicine.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Research Tirzepatide

New-U Research Compounds catalogues tirzepatide as Tirzepatide - sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with the per-batch Certificate of Analysis published online. Tracked worldwide delivery. Research use only - all claims made on this site are for testing and research use only.

Research-grade · >99% HPLC purity · COA per lot

Buy Tirzepatide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research